Previous 10 | Next 10 |
2023-08-01 19:01:20 ET Summary A PDUFA date of January 3, 2024 has been established by which FDA will decide upon by then whether or not cosibelimab should be approved for the treatment of cSCC. It is said that the cutaneous squamous cell carcinoma market in the U.S. alone could r...
2023-07-31 13:08:57 ET Gainers: Mallinckrodt ( MNK ) +42% . Fifth Wall Acquisition Corp. III ( FWAC ) +40% . Tupperware Brands Corporation ( TUP ) +40% . GoodRx Holdings ( GDRX ) +37% . Archer Aviation ( ACHR ) +36% . Steakho...
2023-07-31 08:46:52 ET Checkpoint Therapeutics ( NASDAQ: CKPT ) has entered into a definitive agreement for the issuance and sale of an aggregate of ~3.24M shares of its common stock, ~3.24M of Series A and B warrants to purchase up to 3.2M shares, at a purchase price of $3.09...
2023-07-31 08:19:22 ET Checkpoint Therapeutics ( CKPT ) -14% announces $10 Million registered direct offering priced at-the-market. Citius Pharmaceuticals ( CTXR ) -13% . BioNexus Gene Lab Corp. ( BGLC ) -13% . Blue Star Foods Corp. ( BSFC ) -...
WALTHAM, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3...
2023-07-30 04:19:15 ET Summary Checkpoint Therapeutics announced updated, longer-term data for cosibelimab from their pivotal trial in locally advanced and metastatic cutaneous squamous cell carcinoma “cSCC”. The data revealed improved response over time with higher ...
55% objective response rate; 23% complete response rate in locally advanced cSCC 50% objective response rate; 13% complete response rate in metastatic cSCC Cosibelimab continues to demonstrate a favorable safety profile Biologics License Application currently under review ...
Results support comparability of cosibelimab 800 mg every-two-week and 1200 mg every-three-week dosing regimens Biologics License Application for cosibelimab under review by U.S. FDA; PDUFA goal date of January 3, 2024 WALTHAM, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Checkpoint T...
2023-05-23 16:08:48 ET Checkpoint Therapeutics ( NASDAQ: CKPT ) said Tuesday it has priced the offering of common stock and warrants to raise $10 million. The company will offer 3,256,269 shares of its common stock or pre-funded warrants in lieu thereof, Series A warrants to p...
WALTHAM, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,...
News, Short Squeeze, Breakout and More Instantly...
Checkpoint Therapeutics Inc. Company Name:
CKPT Stock Symbol:
NASDAQ Market:
Checkpoint Therapeutics Inc. Website:
WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review Check...
Collaboration explores the potential synergistic effects of Checkpoint’s anti-PD-L1, cosibelimab, in combination with the autologous T cell therapy, Immuncell-LC YONGIN, South Korea and WALTHAM, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- GC Cell (KRX: 144510.KS) and Checkpoin...
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has entered into a definitive agreement with a single healthcare-dedicated institutional in...